units and nuclear-8.6 billion units. As far a« private parties are concerned, we are having an open mind. If they can bring in resources, additional resources, we are willing to consider their requests on merits.

MR, CHAIRMAN: All right. Question No. 207. Mr. Balram. Not here.

*207. *[The questioner {Shri N. E. Bahrain) was absent. Far answer* vide *Col.* 39-40 infra].

MR. CHAIRMAN: Question No. 208 Mr. D' Souza.

Formulations by M/s. Glaxo

*208. DR. JOSEPH LEON D' SOUZA: Will the Minister of INDUSTRY be pleased to state:

(a) the names of formulations being manufactured by M/s. Glaxo based on Betamethasone Alcohol, Valerate and Di-sodium;

(b) what was the consumption of each of these drugs by the company during the last three years, year-wise;

(c) what was the sales turnover of formulations based on these drugs during the last three years, year-wise;

(d) whether his Ministry have flexed the » prices of these drugs, if so, the price fixed for each drug and what price was take* in the formulation prices;

(e) whether M/s. Glaxo is manufactoring any Vitamin preparations if so, the name of each formulation and what was the total sales of Vitamin preparations dur ing the last three years, year-wise;

(f) whether it is a fact that M/s. Glaxo is manufacturing certain Anti-TB formu lations as well as essential seras and T»c-cines; and

(g) if so, the name of each product and sales turnover of each during the last three years, year-wise?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS (SHRI R. K. JAI-CHANDRA SINGH): (a) to (g) A statement is laid on the Table of the Rajya Sabha.

Statement

(a) A Statement giving the details is attached at Annexure-I.

(b) To the extent information is availa-ble, during the year ending June, 19M consumption of these drugs by M/s. Glaxo Laboratories India Ltd. was as follows:—

(i) Betamethasone Alcohol	120.110 kgs.
(ii) Betamethasone Disodium Phosphate	228.016 kgs.
(iii) Betamethasone 17-Valerate	260.666 kgs.

(c) Sales turnover of individual formula-tions is not monitored.

(d) The followni prices were fixed for these drugs on 12-5-1981 under the Drugs (Prices Control) Order, 1979:—

(i) Betamethasone Alcohol	Rs. 113 34 per gm.
(ii) Betamethasone Disodium Phosphate	Rs. 126.23 per gm.
(iii) Betamethasone 17 Valerate	Rs. 105 85 per gm.

The formulation prices are presently based on the following prices of these bulk drugs, based on the stay granted by the Delhi High Court against the reduction in prices of the bulk drugs and formula-tions:—

(i) Betamethasone Alcohol	Rs. 134.28 per gm.
(ii) Betamethasone Disodium Phosphate	Rs. 225.00 per gm.
(iii) Betamtethasone 17 Valerate	Rs. 220.00 per gm.

(e) A Statement giving the names of Vitamin preparations manufactured by M/s. Glaxo Labs, is at Annexure-II The sales turnover of individual formulations and as such various therapeutic groups like Vitamins are not monitored.

(f) Yes, Sir.

(g) To the extent information a available, names of the products and sales turnover during the last three years is given below:

(Sales Turnover-Rs. lakhs)

Sl.No.	Name of the formulation	YEAR		
		1981-82	1982-83	1983-84
1	Comycin-3 Syrup	14.7	28.5	46.0
2	Crystapen V Granules	22.7	23.9	31.6
3	Triple Antigen	38.6	29.0	35.2
4	Tetanus	49.6	45.5	49.8
5.	Munomycin Inj.	(Sale of available stock)	0.40 (1984)	0.46 (1985)

Annexure-I

1. **Formulations based Betamethasone Alcohol:—**

   (a) Betnelan Tabs.
   (b) Betnesol Eye/Ear drops.
   (c) Betnesol Eye ointment.
   (d) Betnesol—N Eye/ear drops.
   (e) Betnesol Eye ointment.
   (f) Betnesol Nasal Drops.
   (g) Betnesol Oral drops.
   (h) Betnetin Tabs.

2. **Formulations based on Betamethasone Disodium Phos:—**

   (a) Betnesol Injection.
   (b) Betnesol Tabs.

3. **Formulations based on Betamethasone Valerate:—**

   (a) Betnovate Skin Ointment.
   (b) Betnovate Skin Ointment cream base with Neomycin Sulphate.
   (c) Betnovate Skin Ointment with Chinoform.
   (d) Betnovate Scalp Application.
   (e) Beta Derobin Ointment.

Annexure-II

Name of Vitamin formulations

1. Calci-ostevin with vitamin B12 Injection
2. B. Complex Glaxo Liquid
3. Livogen Injection
4. Macrabin Liquid
5. Ostocalcium B12 Syrup
6. Prepalin Forte Injection
7. Vibelan Injection
8. Berin Injection
9. Berin Tabs.
10. Celin Tablets
11. Adexolin Capsules (for Therapeutic use)

12. Adexolin Liquid (for Paediatric use)
13. Cobadex Forte Capsules
14. Complex B. Glaxo Tabs.
15. Complex B. Forte Glaxo Tabs.
16. Haliborange Tonic.
17. Macrabin Injection.
18. Macrafolin Iron Tablets
19. Ostocalcium Tabs.
20. Vitneurin Injection.

21. Livogen Tonic
22. Prepalin Capsules.
23. Macraberin Forte Injection.
24. Macraberin Tabs (For therapeutic use)
25. Multivite FM Capsules
26. Vibelan forte with 'C capsules.

27. Viteolin Capsules.
28. Becadex Forte Capsules.
29. Becadex Tabs.
30. Becadexamin Capsules,
31. Becadex Drops.
32. Becadex Syrup.
33. Oastina Tabs.
34. Minadex Syrup.
35. Livogen Caps.

DR. JOSEPH LEON D'SOUZA: Mr. Chairman, Sir, licences are being granted from time to time for the production of drugs, with a definite capacity ceiling on production. Will the honourable Minister appreciate the fact that M/s Glaxo is manufacturing lucrative formulations containing betamethasone for above the licensed capacity? What action has been initiated against this Company?

Then, Sir, despite the existence of the mandatory provision that 20 per cent of the total siles turnover of a company shall be deployed in the manufacture of essential drugs urgently needed by the country, M/s Glaxo has miserably failed to comply with this. Why has the Government overlooked this important discrepancy?

SHRI R. K. JAICHANDRA SINGH: Sir, there are four companies to whom we have issued licences which I will mention 6 R. S.—2.

just now. M/s Glaxo Laboratories has got a licence for the production of 425 kgs. and the production capacity in 1984-85 is 712 kgs. It is true that they are producing far in excess of the licensed capacity.

DR. JOSEPH LEON D'SOUZA: Cor rect.

SHRI R. K. JAICHANDRA SINGH: Then, some firms in Tamil Nadu and others'have also a capacity of 20 kgs. and they are producing 20 kgs. Ml- Cadla Laboratories have been given 200 kg., but they are not producing anything. There is a small-sector unit which is producing 23.66 kgs. It is true, as I said earlier, that M/s Glaxo Laboratories is producing much beyond the capacity. But, Sir, under the industrial policy, re-endorsement would be granted to them and, also in respect of these items, there are still imports. So, the question is whether we should spend more money in foreign exchange or we should allow a particular company to expand. So, the Government has taken the stand that it would be better to save foreign exchange and that is why this is there.

MR. CHAIRMAN; Yes, Mr, D'Souza, put your second supplementary.

DR. JOSEPH LEON D'SOUZA: Sir, I have put a specific question which has not been answered. I am going to repeat it in my second supplementary. Twenty per cent of the annual turnover of a company shall be deployed in the production of essential drug. Why has this mandatory provision not been implemented? It is mand?tory, Sir.

MR. CHAIRMAN: Now put your second supplementary.

DR. JOSEPH LEON D'SOUZA: I only ask a short question. Will the honourable Minister assure us that either he regularises the excess capacity if the company comes to him or, if it does not do so. whether the licence which very clearly says that "the licence will standi revoked if a condition has not been fulfilled" will stand revoked?

SHRI R. K. JAICHANDRA SINGH: While answering the first part of the question I have said that the question of re-endorsing the capacity will be considered.

MR. CHAIRMAN: The point is why the company has not complied th the statutory requirement that 20 per cent of its capital should be employed that production of ....

SHRI R. K. JAICHANDRA SINGH: I don't have any specific information on this but I will pass it on to the honourable Member later.

SHRI JAGESH DESAI: I am surprised to find that the Government has fixed the price under the Drug Control Act for Betamethasone Disodium Phosphate at Rs. 126-03 P. per gm. whereas for the purpose of formulation the price has been taken at Rs. 225, i.e. Rs. 100 more. Similarly, for item No. (iii) Betamethasone 17 Valerate under the Drug Control Act the price has been fixed at. Rs. 105-85 P. per gm. but for the purpose of formulation it has been taken at Rs. 220|- The price will depend on the cost of purchase plus import duty freight, etc. 1 would like to know whether the Government has pleased with the High Court that the prices which we have fixed are on this basis. If in spite of that if the High Court unfortunately arbitrarily fixes the prices . . .

MR CHAIRMAN; You don't express any opinion about what the High Court will do. Mr Minister you may answer the question . . .

SHRI R. K. JAICHANDRA SINGH: Of the two prices which the honourable Member quoted one is the price under the DPC of 1979 and the other is the price of 1970 and the matter is still in the High Court. The cases are coming up for hearing sometime next month. The company has gone in appeal to the High Court.

SHRI N. K. P. SALVE: This drug business is appearing in the House for the ninth time . . .

MR. CHAIRMAN: I don't know.

SHRI N. K. P. SALVE: If the conscience of the Government is not drugged may I know for the last time whether the Government is going to be strict about the implementation of the norms, and terms laid down in the licence?

SHRI R. K. JAICHANDRA SINGH: As I said in my earlier reply to Q. No. 222, there are a lot of areas, grey areas, where the Government has not been able to implement the Drug Control. We are considering this and in the new Drug Policy we hope to take care of that.

MR. CHAIRMAN: Mr, Salve, in fact, you were not here when the Minister said in the new policy which they are formulating they will take into account this problem.

Study of Judicial Reforms by Law Commission

*209. SHRI B. SATYANARAYAN REDDY: t SHRI L. GANESAN:

Will the Minister of LAW AND JUSTICE be pleased to state:

(a) whether it is a fact that Government has entrusted the entire question of judicial reforms to Law Commission;

(b) if so, by when it i_s expected to submit its report on Judicial Reforms; and

(c) whether any guidelines have been forwarded in this regard by the Government to Law Commission; if so, what are the details thereof?

THE MINISTER OF STATE IN THE MINISTRY OF LAW AND JUSTICE (SHRI H. R. BHARDWAJ); (a) Yes, Sir.

(b) No time limit has been stipulated, as such, However, the Law Commission has been requested to study the question of judicial reforms and make its recommendations available to the Government, as early as possible.

tThe question was actually asked on 'he floor of the House by 'Shri B, Satyana-rayan Reddy.